Obesity Management and Redux
Regular price
12.250 KD
inc. VAT
Couldn't load pickup availability
Table of contents
- Cover
- Contentsxiii
- Contributorsv
- Prefacevii
- Introduction: History of Dexfenfluraminexi
- Chapter 1. New Trends in the Management of Obesity in the United States1
- Chapter 2. The Impact of Obesity and the Introduction of Redux TM in the United States7
- Part I: Redux TM: Pharmacological Profile11
- Chapter 3. The Pharmacology of Dexfenfluramine13
- Chapter 4. Neurochemical Mode of Action of Drugs which Modify Feeding through the 5-HT System17
- Chapter 5. Dexfenfluramine: Biological Regulator of Risk Factors for Overeating23
- Part II: Methods for Assessing Neurochemical Changes and their Effect33
- Chapter 6. Advancement of Knowledge on Fenfluramine and Dexfenfluramine Effects on Brain Chemistry35
- Chapter 7. Reactive Gliosis as an Indicator of Neurotoxicity43
- Chapter 8. Dexfenfluramine Effects on Serotonin Neurons: A Long-term Immunohistochemical Analysis49
- Chapter 9. Behavioural and Other Functional Effects of Low and High Doses of Fenfluramine and Dexfen57
- Chapter 10. The Use of Pharmacokinetics in the Assessment of Dexfenfluramine Safety65
- Part III: ReduxTM: Therapeutic Efficacy81
- Chapter 11. Overview of the Clinical Data83
- Chapter 12. INDEX Study: Weight Data and Effects on Risk Factors and Comorbidities87
- Chapter 13. An 18-month Study of the Effects of Dexfenfluramine on Cognitive Function in Obese Ameri93
- Chapter 14. Fenfluramines, Obesity and Primary Pulmonary Hypertension: Risks and Benefits99
- Chapter 15. Overview of the Safety Data105
- Part IV: Benefit/Risk Ratio of the Treatment of Obesity113
- Chapter 16. Benefits and Risks of Treating Obesity115
- Chapter 17. Round Table Discussion121
Redux is a revolutionary new anti-obesity drug that has just been approved (July 1996) by the FDA. It is the first weight management drug treatment to be launched in the United States in 20 years and is not addictive, unlike earlier drugs used for this purpose. Obesity Management and Redux includes a brief introduction which leads up to its discovery and includes an overview of new trends in obesity management. The book lists the pharmacological profile of the drug, given by experts involved in monitoring the effects of the drug on the brain neurotransmitters, as well as detailing the results (including safety data) of the various clinical trials.
Key Features
* Covers all aspects of a revolutionary new drug
* Lists pharmacological profile of the drug
* Includes safety data
* Projects future trends in weight management
Key Features
* Covers all aspects of a revolutionary new drug
* Lists pharmacological profile of the drug
* Includes safety data
* Projects future trends in weight management